Search
midostaurin (Rydapt)
Indications:
- acute myeloid leukemia (AML), FLT3 mutation positive
- for use in combination with standard cytarabine & daunorubicin induction & cytarabine consolidation
- aggressive systemic mastocytosis or systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia
Dosage:
- AML:
- 50 mg every 12 hours* on days 8-21 of each induction cycle with cytarabine & daunorubicin & on days 8-21 of each consolidation cycle with high-dose cytarabine
- systemic mastocytosis or mast cell leukemia:
- 100 mg PO BID*
- continue until disease progression or unacceptable toxicity
* with food
Capsules: 25 mg
Adverse effects:
- >= 20%
- febrile neutropenia
- nausea, vomiting
- mucositis
- headache
- petechiae
- musculoskeletal pain
- epistaxis
- device-related infection
- hyperglycemia
Drug interactions:
- strong CYP3A4 Inhibitors may increase exposure to midostaurin & its active metabolite
Mechanism of action:
- inhibits FLT3 receptor tyrosine kinase
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
antineoplastic agent (chemotherapeutic agent)
tyrosine kinase inhibitor
Database Correlations
PUBCHEM correlations
References
- Gotlib J, Kluin-Nelemans HC, George TI et al
Efficacy and Safety of Midostaurin in Advanced Systemic
Mastocytosis.
N Engl J Med. 2016 Jun 30;374(26):2530-41.
PMID: 27355533 Free Article
- O'Neil A, Klil-Drori AJ.
AML: FLT3 Inhibitor Shows 'Robust' Activity as Frontline
Therapy - Overall response rate 100% in patients with FLT3-
mutated disease in early research.
MedPage Today. Jan 17, 2018
https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/70559
- RYDAPT prescribing information
https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/rydapt.pdf